Trends in Pharmacological Sciences
ReviewNon-genomic loss of PTEN function in cancer: not in my genes
Introduction
Cancer is believed to develop because some cells within an organism become aberrant and hyperproliferative through the accumulation of genetic and epigenetic changes. The genes most frequently modified in cancer are frequently categorised into two groups: oncogenes, in which a gain of function drives tumour formation and tumour suppressors, in which a loss of function promotes tumour development. The lipid phosphatase, PTEN, is a tumour suppressor originally identified by two research groups in 1997 1, 2. Mutations of the PTEN gene occur at some significant frequency in almost all human tumour types and mutation of at least one allele occurs in one third or more of breast, colon, prostate and lung tumours {[3] and the Cosmic (collection of Somatic Mutations in Cancer) database; http://www.sanger.ac.uk/genetics/CGP/cosmic/}. Accordingly, in a recent cancer genomics study aiming to distinguish between deletions driven by chromosomal instability and those driven by phenotypic selection, PTEN was proposed to be the tumour suppressor locus in the human genome with the greatest selection for loss [4].
Biochemically, PTEN is a phosphatase that dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PIP3), the lipid product of the class I phosphoinositide 3-kinases (PI3K) [5]. This discovery was rapidly followed by a wealth of genetic and cell-based evidence showing that PTEN is a ubiquitous inhibitor of PI3K-dependent signalling [6]. PI3K/PTEN signalling (and the PIP3 lipid they control) influence cell behaviour through a large and diverse set of PIP3-binding proteins, the best characterised of which are the AKT protein kinases 7, 8, 9. In this way, PI3K and PTEN orchestrate cell responses to growth factors, cytokines, integrins and other intercellular mediators and contribute to the growth, motility, survival and metabolic responses of many cell types. PTEN also has robust protein phosphatase activity in vitro and has been proposed to play a tumour suppressor role in the nucleus, independently of plasma membrane-localised PIP3 10, 11, 12, 13. However, the significance of these other mechanisms of action is currently unclear and space constraints do not allow us to consider them further here. The loss of PTEN function in tumours should also be viewed in the context of the broader PI3K pathway, in which an alternative route of PIP3 metabolism is provided by the family of phosphoinositide 5-phosphatases, in particular the SHIP enzymes, which convert PIP3 to the alternate signal PI(3,4)P2 (Figure 1).
Section snippets
Partial loss of PTEN function
For many years the ‘gold standard’ of evidence for functional dysregulation in human tumours has been genetic mutation data, in large part due to apparent clarity provided by the identification of novel sequence variants and the usually robust nature of DNA sequence data. Accordingly, it has been clear for many years that the great majority of PTEN mutations identified in tumours inhibit the function of the enzyme 14, 15. However, improvements in other technologies in tumour pathology,
PTEN function: constitutive activity and post-translational inhibition?
The PTEN gene encodes a single 403 amino acid protein (Figure 2). Genetic deletion or RNAi-mediated knockdown of PTEN in many (but not all) unstimulated cultured cells or tissues leads to robust increases in PIP3-dependent AKT phosphorylation and (where measured) intracellular PIP3 levels 35, 36, 37. This strongly argues that PTEN plays a continuous physiological role in suppressing PIP3 levels in many cell types and is consistent with the constitutive activity of PTEN purified from multiple
Epigenetic and transcriptional regulation of PTEN
In addition to gene mutations or deletions, and protein post-translational modifications and protein–protein interactions affecting its activity and stability, PTEN undergoes a complex regulation by multiple epigenetic and transcriptional mechanisms (Figure 3). This additional level of regulation appears to play a crucial role in diverse cancer or metabolic disorders in which PTEN expression is altered with no apparent muations or deletions of the gene.
Cancer therapeutics targeting PTEN function?
The PI3K signalling pathway appears to contribute to driving the formation of most human tumours and frequently to resistance of these tumours to existing therapies 19, 127. The pathway is therefore the target of intense drug discovery activity 128, 129. The emergence of evidence, discussed in this review, that tumour development is promoted by modifiers of PTEN function has raised the possibility of these modifiers as novel drug targets. The most appealing targets would appear to be functional
Concluding remarks
In summary, novel insight into the mechanisms leading to loss of PTEN function in tumours is not only likely to identify novel therapeutic approaches but also provides a deeper understanding of oncogenic PI3K/PTEN signalling that will assist the development and eventual use of the many agents targeting this pathway that are under development. It seems likely that continued intense activity in this broad research field will provide many areas of progress and eventually clinical success stories.
Acknowledgements
Work in the Leslie laboratory is supported by the UK Medical Research Council (grant G0801865), the Association for International Cancer research (grant 08-0497) and the pharmaceutical companies of the Dundee Signal Transduction Therapy Consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, and Pfizer) and in the Foti laboratory by the Swiss National Science Foundation (grant No. 310000-120280/1) and the Swiss Research against Cancer Foundation (grant No.
References (137)
Tenets of PTEN tumor suppression
Cell
(2008)- et al.
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
J. Biol. Chem.
(1998) - et al.
PTEN: the down side of PI 3-kinase signalling
Cell Signal.
(2002) - et al.
AKT/PKB signaling: navigating downstream
Cell
(2007) Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging
Mol. Cell
(2008)PTEN enters the nuclear age
Cell
(2007)The significance of PTEN's protein phosphatase activity
Adv. Enzyme Regul.
(2009)Ubiquitination regulates PTEN nuclear import and tumor suppression
Cell
(2007)Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast
Am. J. Pathol.
(1999)Cowden syndrome
Semin. Oncol.
(2007)
A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease
J. Invest. Dermatol.
Rak functions as a tumor suppressor by regulating PTEN protein stability and function
Cancer Cell
NEDD4-1 Is a proto-oncogenic ubiquitin ligase for PTEN
Cell
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Cell
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association
Cell
The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome- mediated degradation
J. Biol. Chem.
Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress
J. Biol. Chem.
X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization
J. Biol. Chem.
E3 ligase Nedd4 promotes axon branching by downregulating PTEN
Neuron
Functional interaction of phosphatase and tensin homologue (PTEN) with the E3 ligase NEDD4-1 during neuronal response to zinc
J. Biol. Chem.
Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells
J. Biol. Chem.
Differential redox regulation within the PTP superfamily
Cell Signal.
Redox redux: revisiting PTPs and the control of cell signaling
Cell
Reversible inactivation of the tumor suppressor PTEN by H2O2
J. Biol. Chem.
Phosphorylation of the survival kinase Akt by superoxide is dependent on an ascorbate-reversible oxidation of PTEN
Free Radic. Biol. Med.
Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain
J. Biol. Chem.
Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex
J. Biol. Chem.
Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta
J. Biol. Chem.
Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein
J. Biol. Chem.
Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type
Blood
Promoter methylation and silencing of PTEN in gastric carcinoma
Lab. Invest.
Considerations when analyzing the methylation status of PTEN tumor suppressor gene
Am. J. Pathol.
SALL4 is a key regulator of survival and apoptosis in human leukemic cells
Blood
Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN
J. Hepatol.
Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN
Curr. Biol.
Insulin-like growth factor-II regulates PTEN expression in the mammary gland
J. Biol. Chem.
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
Science
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
Nat. Genet.
Signatures of mutation and selection in the cancer genome
Nature
Signalling through class I PI3Ks in mammalian cells
Biochem. Soc. Trans.
Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression
J. Cell Sci.
Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay
Cancer Res.
PTEN function: how normal cells control it and tumour cells lose it
Biochem. J.
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Proc. Natl. Acad. Sci. U.S.A.
The role of PTEN signaling perturbations in cancer and in targeted therapy
Oncogene
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Nature
Genetic interactions between Pten and p53 in radiation-induced lymphoma development
Oncogene
Pten dose dictates cancer progression in the prostate
PLoS Biol.
Cancer and Lhermitte–Duclos disease are common in Cowden syndrome patients
Hered. Cancer Clin. Pract.
Subtle variations in Pten dose determine cancer susceptibility
Nat. Genet.
Cited by (130)
Proteomic and yeast 2-hybrid screens to identify PTEN binding partners
2024, Advances in Biological RegulationMechanisms of PTEN loss in cancer: It's all about diversity
2019, Seminars in Cancer BiologyConformational Dynamics and Allosteric Regulation Landscapes of Germline PTEN Mutations Associated with Autism Compared to Those Associated with Cancer
2019, American Journal of Human GeneticsCitation Excerpt :The regulation of the enzymatic activity and functional diversity of PTEN is complex and involves multiple cellular processes and interactions with other proteins. Hence, deficiency of any of these functions contributes to disease.15–17 In fact, PTEN structure-function analyses reveal distinctive functional patterns that correlate with variants found in the catalytic active site.
Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System
2019, Molecular Therapy Nucleic AcidsCitation Excerpt :CRISPR-treated SK-MEL-28 cells exhibited fewer and smaller colonies than control when grown in the presence of the B-Raf inhibitor dabrafenib, and this effect was even more pronounced for both the PI3K/mTOR inhibitor dactolisib and for the combination dabrafenib and dactolisib treatment. By dephosphorylating phosphoinositides and protein substrates on receptor tyrosine kinases and integrins, PTEN is a master regulator of downstream PI3K/AKT/mTOR- and Ras/Raf/MAPK-signaling pathways, controlling survival, motility, and drug resistance mechanisms.4–7,76 As PTEN possesses intrinsic enzymatic activity, even small changes in functional PTEN levels in cancer cells can elicit profound alterations in cancer progression.6,21,22